StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30
$2.98−0.11 (-3.56%)

Close on Nov 18, 2026Market cap $295.46MP/E –Yield –

X4 Pharmaceuticals net income

Net income is the profit left for shareholders after every expense, interest and tax.

X4 Pharmaceuticals's net income for the twelve months ending Sep 30, 2026 was -$80.52M. For fiscal 2025 it was -$79.20M. The highest annual figure on record is -$21.99M in fiscal 2017.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$79.20M–
FY2024Dec 31, 2024-$37.45M–
FY2023Dec 31, 2023-$101.17M–
FY2022Dec 31, 2022-$93.87M–
FY2021Dec 31, 2021-$88.70M–
FY2020Dec 31, 2020-$62.13M–
FY2019Dec 31, 2019-$52.81M–
FY2018Dec 31, 2018-$33.29M–
FY2017Dec 31, 2017-$21.99M–
FY2016Dec 31, 2016-$22.98M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$20.20M–
Q2 FY2026Jun 30, 2026-$16.16M–
Q1 FY2026Mar 31, 2026-$20.24M-7277.7%
Q4 FY2025Dec 31, 2025-$23.93M–
Q3 FY2025Sep 30, 2025-$29.82M–
Q2 FY2025Jun 30, 2025-$25.74M-128.3%
Q1 FY2025Mar 31, 2025$282.00K–
Q4 FY2024Dec 31, 2024-$39.82M–
Q3 FY2024Sep 30, 2024-$36.70M–
Q2 FY2024Jun 30, 2024$90.83M–
Q1 FY2024Mar 31, 2024-$51.77M–
Q2 FY2023Jun 30, 2023-$55.71M–
Q1 FY2023Mar 31, 2023-$24.02M–
Q4 FY2022Dec 31, 2022-$29.10M–
Q3 FY2022Sep 30, 2022-$21.59M–
Q2 FY2022Jun 30, 2022-$21.21M–
Q1 FY2022Mar 31, 2022-$21.97M–
Q4 FY2021Dec 31, 2021-$30.21M–
Q3 FY2021Sep 30, 2021-$20.18M–
Q2 FY2021Jun 30, 2021-$19.64M–
Q1 FY2021Mar 31, 2021-$18.68M–
Q4 FY2020Dec 31, 2020-$18.40M–
Q3 FY2020Sep 30, 2020-$17.45M–
Q2 FY2020Jun 30, 2020-$15.14M–
Q1 FY2020Mar 31, 2020-$11.14M–
Q4 FY2019Dec 31, 2019-$10.84M–
Q3 FY2019Sep 30, 2019-$17.71M–
Q2 FY2019Jun 30, 2019-$13.38M–
Q1 FY2019Mar 31, 2019-$10.87M–
Q4 FY2018Dec 31, 2018-$9.36M–
Q3 FY2018Sep 30, 2018-$8.60M–
Q2 FY2018Jun 30, 2018-$6.03M–
Q1 FY2018Mar 31, 2018-$7.37M–
Q4 FY2017Dec 31, 2017-$11.19M–
Q3 FY2017Sep 30, 2017-$11.60M–
Q2 FY2017Jun 30, 2017-$5.71M–
Q1 FY2017Mar 31, 2017-$5.39M–

More X4 Pharmaceuticals figures

See a number that looks wrong?